We read with interest the Article by Ray and colleagues,1 which showed that bempedoic acid compared with placebo reduced the risk of cardiovascular events in statin-intolerant patients with type 2 diabetes without previous atherosclerotic cardiovascular disease. They also showed treatment-related improvements in LDL cholesterol and non-HDL cholesterol and improvements in high-sensitive C-reactive protein concentrations, all independent of patients’ glycaemic and cardiovascular disease status. Because existing treatments, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, often fail to sufficiently reduce LDL cholesterol concentrations when used as monotherapy, Ray and colleagues’ findings concerning bempedoic acid are promising for clinical practice.